top of page

Slipstream™ Technology

Novel Technology to Deliver Safer Cell and Gene Therapies to Treat Cancer and Rare Diseases

TransCytos’ Slipstream™  platform  technology  enables  personalized therapies through virus-free modification  (“transfection”) of the patient's own immune cells to expand their immune capabilities (i.e., CAR-T cells).

  • TransCytos technology uses a proprietary hydrodynamic process to modify cells, delivering DNA, RNA, and proteins into primary cells for new gene editing or replacement (“CRISPR”).

  • Our technology improves safety, minimizes risks, and reduces costs associated with viral gene delivery.

  • Without viruses, our technology can deliver repeat treatments, such as multiple genes needed for complex diseases, cancer relapse, and repeated treatments for young children who can now live to old age.

  • Partnering with drug developers will make the rapid creation and delivery of personalized cures possible for a range of cancer, infectious, autoimmune, and rare genetic diseases – without the need for viruses, chemo or radiation.

Competitive Advantages

Slipstream™ will be a broadly applicable therapy development and delivery platform in multi-trillion-dollar markets, yielding benefits to our patients and better profit margins for our partners. In addition, therapy costs are expected to be low enough to be paid for by insurance – a benefit for our partners as their markets expand.

Our devices and processes will also be used when partnering with R&D labs, increasing the rate of new therapy generation.

TransCytos –
A Platform for Treating Cancer, Autoimmunity and Rare Diseases

TransCytos’ business strategy is patient-focused, seeking partners for the co-development and delivery of cell and gene therapies for cancer and rare diseases.


  • Through eliminating viruses in the cell modification process TransCytos’ Slipstream™ devices enable safe and affordable, high-impact treatments in hospitals; our goal is to drive delivery costs down so far that insurance will pay for the treatments.

  • In the lab, our technology successfully transfected T cells isolated from human blood to create CAR-T cells that kill tumor cells.

  • TransCytos first developed the technology to transfect primary neurologic cells, including glia cells and astrocytes, two cell types that are easy to damage and extremely difficult to modify genetically.

  • Current work includes developing protocols for human organ primary cells so that genetic modification can be used in various human diseases.

  • Just as creating CAR-T cells was an excellent demonstration of our technology in a therapeutic application in cancer, TransCytos plans to partner with groups and companies developing genetic therapies for a range of diseases. Plans include other human cells:

    • CAR-NK cells for oncology.

    • CAR-T reg cells for severe autoimmune disease.

    • Gene therapies (CD34+ stem cells or liver stem cells) for inherited disease (i.e., ADA-SCID, thalassemia, Gaucher disease).

Screenshot 2023-02-01 at 11.17.39 AM.png

Let's Change the World Together

bottom of page